Herpes Simplex Virus Cure Research: Current Progress and Promising Avenues

No cure exists yet for HSV-1 (oral) or HSV-2 (genital), but multiple strategies are in preclinical/clinical development.

Latent reservoir in sensory ganglia (non-dividing neurons) – hard to target without neurotoxicity.
Immune evasion (ICP47 blocks TAP, US3 inhibits MHC-I).
Need for lifelong safety in otherwise healthy people.

While a sterilizing cure remains elusive, functional cure (no reactivation, no shedding, no transmission) is a realistic near-term goal.

Strategy	Mechanism	Status
Improved antivirals	Helicase-primase inhibitors (pritelivir, amenamevir) – novel target, active vs. resistant strains	Phase 2/3
Gene editing	CRISPR/Cas9, meganucleases target latent HSV genome in neurons	Preclinical (mouse models show >90% reduction)
Therapeutic vaccines	Boost CD8⁺ T-cell control of latency/reactivation (e.g., HSV-2 gD2-deleted, mRNA)	Phase 1/2
Epigenetic silencing	HDAC inhibitors, heterochromatin induction to lock virus in latency	Preclinical
Combination	Antiviral + immune modulator (e.g., TLR agonist) for "shock and kill"	Early clinical